Department of Pathology, Aberdeen Royal Infirmary and Aberdeen University Medical School, Aberdeen, UK.
Institute for Pathology, University Hospital Basel, Basel, Switzerland.
Ann Oncol. 2014 Sep;25(9):1681-1690. doi: 10.1093/annonc/mdu145. Epub 2014 Apr 8.
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.
为了补充所有肿瘤类型的现有治疗指南，ESMO 组织共识会议，专注于每种肿瘤类型的具体问题。第二次 ESMO 肺癌共识会议于 2013 年 5 月 11 日至 12 日在卢加诺举行。共有 35 名专家参加了会议，就非小细胞肺癌（NSCLC）患者管理的几个问题进行了讨论，分为四个领域：病理学和分子生物标志物、早期疾病、局部晚期疾病和晚期（转移性）疾病。针对每个问题，都提出了建议，包括对推荐等级和证据水平的参考。本共识文件主要侧重于与肺癌诊断相关的病理学和分子生物标志物的建议，主要是非小细胞癌。
